The clinically active PARP inhibitor AG014699 ameliorates cardiotoxicity but does not enhance the efficacy of doxorubicin, despite improving tumor perfusion and radiation response in mice (Q35622211)
Jump to navigation
Jump to search
scientific article published on 16 September 2011
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | The clinically active PARP inhibitor AG014699 ameliorates cardiotoxicity but does not enhance the efficacy of doxorubicin, despite improving tumor perfusion and radiation response in mice |
scientific article published on 16 September 2011 |
Statements
1 reference
The clinically active PARP inhibitor AG014699 ameliorates cardiotoxicity but does not enhance the efficacy of doxorubicin, despite improving tumor perfusion and radiation response in mice (English)
1 reference
Kaye J Williams
1 reference
Majid Ali
1 reference
Marzieh Kamjoo
1 reference
Huw D Thomas
1 reference
Suzanne Kyle
1 reference
Ivanda Pavlovska
1 reference
Muhammed Babur
1 reference
Brian A Telfer
1 reference
Nicola J Curtin
1 reference
16 September 2011
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference